157 related articles for article (PubMed ID: 34793589)
21. Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance.
Wrigley E; Verspaget HW; Jayson GC; McGown AT
J Cancer Res Clin Oncol; 2000 Dec; 126(12):717-21. PubMed ID: 11153145
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
[TBL] [Abstract][Full Text] [Related]
23. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
24. The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis.
Xing L; Mi W; Zhang Y; Tian S; Zhang Y; Qi R; Lou G; Zhang C
J Cell Mol Med; 2020 Sep; 24(17):9839-9852. PubMed ID: 32762026
[TBL] [Abstract][Full Text] [Related]
25. The prognostic nomogram in platinum-resistant ovarian cancer: how to develop and validate?
Wen KC; Sung PL; Lai HC
Chin Clin Oncol; 2021 Jun; 10(3):31. PubMed ID: 32648447
[No Abstract] [Full Text] [Related]
26. HOXB2 promotes cisplatin resistance by upregulating lncRNA DANCR in ovarian cancer.
Li X; Zheng Z; Zhou W; Huang H; Zhou Y; Xu Q; Zhu X; Teng Y
J Ovarian Res; 2024 Jun; 17(1):124. PubMed ID: 38851728
[TBL] [Abstract][Full Text] [Related]
27. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
28. Integrated Bioinformatics Analysis for Identification of the Hub Genes Linked with Prognosis of Ovarian Cancer Patients.
Li X; Wang Q; Wu Z; Zheng J; Ji L
Comput Math Methods Med; 2022; 2022():5113447. PubMed ID: 35047055
[TBL] [Abstract][Full Text] [Related]
29. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
Wang Y; Zhao G; Condello S; Huang H; Cardenas H; Tanner EJ; Wei J; Ji Y; Li J; Tan Y; Davuluri RV; Peter ME; Cheng JX; Matei D
Cancer Res; 2021 Jan; 81(2):384-399. PubMed ID: 33172933
[TBL] [Abstract][Full Text] [Related]
30. Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.
Zhang L; Zhang X; Fan S; Zhang Z
Medicine (Baltimore); 2019 Nov; 98(44):e17803. PubMed ID: 31689861
[TBL] [Abstract][Full Text] [Related]
31. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
32. A seven-gene prognostic model for platinum-treated ovarian carcinomas.
Sabatier R; Finetti P; Bonensea J; Jacquemier J; Adelaide J; Lambaudie E; Viens P; Birnbaum D; Bertucci F
Br J Cancer; 2011 Jul; 105(2):304-11. PubMed ID: 21654678
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer.
Yan X; Yin J; Yao H; Mao N; Yang Y; Pan L
Cancer Res; 2010 Feb; 70(4):1616-24. PubMed ID: 20103635
[TBL] [Abstract][Full Text] [Related]
34. Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.
Zavarikina TM; Khokhlova SV; Tyulyandina AS; Khabas GN; Asaturova AV; Nosova YV; Brenner PK; Kapralova MA; Khodirev DS; Stenina MB
Bull Exp Biol Med; 2021 Oct; 171(6):755-759. PubMed ID: 34709513
[TBL] [Abstract][Full Text] [Related]
35. A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.
Chen S; Wu Y; Wang S; Wu J; Wu X; Zheng Z
J Ovarian Res; 2022 Mar; 15(1):39. PubMed ID: 35361267
[TBL] [Abstract][Full Text] [Related]
36. A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients.
Phillips-Chavez C; Watson M; Coward J; Schloss J
Eur J Clin Pharmacol; 2020 Aug; 76(8):1059-1074. PubMed ID: 32440721
[TBL] [Abstract][Full Text] [Related]
37. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
39. Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
Zhang M; Liu T; Xia B; Yang C; Hou S; Xie W; Lou G
Int J Gynecol Cancer; 2018 Feb; 28(2):323-331. PubMed ID: 29240605
[TBL] [Abstract][Full Text] [Related]
40. Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.
Pereira D; Assis J; Gomes M; Nogueira A; Medeiros R
Eur J Clin Pharmacol; 2016 May; 72(5):545-53. PubMed ID: 26803611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
